Table 4.

Association of prostate cancer risk with genotype polymorphisms and clinical features.

Gene	Polymorphism	Genotype	Gleason score		OR	95% CI	P value	Tumor stage		OR	95% CI	P value
			2–6	7–10				T1-T2b	T2c-T4
SRD5A2	A49T	A/A	20	6	Reference			17	10	Reference
		A/T + T/T	36	34	3.15	1.13–8.78	0.044	26	44	2.88	1.15–7.21	0.039
	V89L	V/V	19	24	Reference			8	36	Reference
		V/L + L/L	37	16	0.34	0.15–0.79	0.020	36	17	0.11	0.04–0.27	0.000
MTHFR	C677T	C/C	25	5	Reference			12	15	Reference
		C/T + T/T	32	34	5.31	1.81–15.56	0.003	33	35	0.85	0.35–2.08	0.895
AR	CAG repeats	≥22 CAGs	19	8	Reference			19	8	Reference
		≤21 CAGs	27	33	2.90	1.10–7.66	0.05	20	40	4.75	1.77–12.72	0.003

OR, odds ratio.